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K e y  M e s s a g e s 
1. Co-amplification at lower denaturation 
temperature-PCR (COLD-PCR) was developed 
for early detection of hepatitis B virus (HBV) 
drug resistance mutations.
2. With a simple alteration of denaturation 
temperature in the thermal cycle, COLD-PCR 
could detect drug resistance mutations that 
existed at a level of 5-10% within a mixed pool, 
compared with a level of ≥25% for conventional 
PCR.
3. In patients prescribed lamivudine or telbivudine, 
COLD-PCR was more sensitive than conventional 
COlD-pCR for early detection of hepatitis B 
virus antiviral drug resistance mutations
DKH Wong *, J Fung, CL Lai, MF Yuen
Introduction
Nucleos(t)ide analogues (NAs) are effective 
therapeutic agents for the treatment of chronic 
hepatitis B virus (HBV) infection. However, long-
term use of NAs is often hampered by the emergence 
of drug resistance mutations, causing potentially 
serious consequences such as liver decompensation 
and mortality. A more sensitive method for early 
detection of drug resistance mutations is needed.
 Conventional PCR amplification of HBV 
DNA followed by direct sequencing of the purified 
amplicons for detection of drug resistance mutations 
has two advantages. First, it can detect any novel 
mutation within the amplicons. Second, it is 
relatively inexpensive. However, it cannot detect a 
low level of mutations that comprise <20% of the 
total viral population. 
 Co-amplification at lower denaturation 
temperature PCR (COLD-PCR) has been used 
for enrichment of a low level of variants within a 
mixed pool of sequences.1 COLD-PCR relies on 
slight changes to the melting temperature (Tm) in 
the DNA sequence caused by mutations within the 
sequence. For each DNA sequence, there is a critical 
denaturation temperature (Tc) below which PCR 
efficiency decreases abruptly.1 Tc is lower than Tm 
and is dependent on the DNA sequence itself. When 
the denaturation temperature of PCR is set to Tc 
(instead of the usual 94ºC), DNA amplicons with 
different mutations will have different amplification 
efficiencies. This property enables selectively enrich 
low-level mutations in a mixed pool. 
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 The principle for COLD-PCR is shown in Fig 
1. Like conventional PCR, COLD-PCR starts with a 
denaturation step at 94ºC. Following denaturation, 
an intermediate hybridisation temperature of 70ºC is 
used to promote cross-hybridisation of mutant and 
wild-type alleles, forming a heteroduplex. Then, with 
a denaturation temperature at Tc, the heteroduplex 
is selectively denatured and subsequently amplified, 
whereas the wild-type homoduplex does not amplify 
efficiently. As a result, mutations that exist in a 
minority are enriched by COLD-PCR and detected 
by subsequent sequencing. 
 This study aimed to (1) develop a modified 
COLD-PCR method to detect common HBV 
drug resistance mutations in patients undergoing 
lamivudine or telbivudine therapy (two of the 
licensed NAs) and (2) compare the performance 
of COLD-PCR with that of the LiPA HBV drug 
resistance assay (Fujirebio Europe, Belgium) and 
conventional PCR. 
Results
The execution of COLD-PCR depends on the 
experimental identification of Tc. Cloned wild-type 
HBV DNA and HBV DNA with representative drug 
resistance mutations were used as templates for 
PCR at different denaturation temperatures. Using 
a conventional denaturation temperature of 94ºC, 
all wild-type and mutant sequences were amplified 
efficiently with Sybr-green-based real-time PCR, 
and experiments were performed with decreasing 
denaturation temperatures. PCR amplification was 
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES
PCR, with a higher mutation detection rate.
4. COLD-PCR is useful for patient monitoring, as it 
is more sensitive than conventional PCR in early 
detection of drug resistance mutations.
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not observed when the denaturation temperature 
<78ºC, which is defined as Tc when amplification 
efficiency decreases abruptly. Thus, the Tc for the 
PCR amplicon was determined to be 78ºC.
 Both COLD-PCR and conventional PCR 
were used to detect HBV mutations in mixtures of 
various proportions of cloned wild-type and mutant 
HBV DNA. Conventional PCR could detect drug 
resistance mutations only when the mutant plasmids 
existed at a level of ≥25% within the mixture, whereas 
COLD-PCR could detect drug resistance mutations 
at a level of 5-10% within the mixture.
 The performance of the LiPA assay, COLD-
PCR, and conventional PCR in detecting drug 
resistance mutations was compared in 106 patients 
treated with lamivudine and 30 patients treated 
with telbivudine. These patients have been followed 
up in our centre and previously reported to have 
virological breakthrough during follow-up.2,3 Among 
these 136 patients, lamivudine/telbivudine-resistant 
mutations rtM204V/I were detected in 129 (95%), 
108 (79%) and 84 (62%) patients by the LiPA assay, 
COLD-PCR, and conventional PCR, respectively. 
Drug resistance mutations were detectable by all 
three methods in 84 patients. To investigate whether 
these three methods can detect early drug resistance 
mutations, we attempted to detect rtM204V/I 
mutations from these 84 patients at 6-12 months 
before the previous mutation detection time points. 
In five samples taken from the earlier time point, 
HBV DNA was not amplifiable by PCR by any of the 
three methods. When analysing the samples taken 
from both time points collectively, COLD-PCR 
was also more sensitive than conventional PCR: 35 
(16%) samples had rtM204V/I detected by COLD-
PCR but not by conventional PCR, while all samples 
with mutations detected by conventional PCR were 
detected by COLD-PCR.
Discussion
Detection of drug resistance mutations is essential in 
the management of patients with antiviral therapy. 
Conventional PCR often cannot detect minority 
variants. In this study, COLD-PCR could detect 
HBV drug resistance mutations at a level of 5-10%, 
whereas conventional PCR could detect HBV 
mutations only at a level of ≥25%.
 Among the three methods tested, the LiPA 
assay had the highest mutation detection rate in 
patients treated with lamivudine or telbivudine 
compared with COLD-PCR and conventional PCR. 
Among the samples with mutations detected by 
LiPA, COLD-PCR could detect mutations in more 
samples than conventional PCR. In particular, there 
were 35 samples with rtM204V/I mutations detected 
by COLD-PCR but not by conventional PCR, while 
all samples with mutations detected by conventional 
PCR were also detected by COLD-PCR. Thus, 
COLD-PCR was more sensitive than conventional 
PCR in detecting drug resistance mutations.
 Although COLD-PCR may not be superior to 
the LiPA assay, it has several advantages. First, it is 
capable of enriching and detecting minority variants 
at all possible positions within the amplicon, whereas 
DNA templates
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FIG.  Principle of co-amplification at lower denaturation temperature PCR: mutation sites in the minority mutant template are 
shown as open circles (the figure is modified from a study by Li et al1; copyright permission to adapt that figure was obtained from 
Macmillan Publishers).
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LiPA is confined to a pre-defined set of variants. 
Second, compared with conventional PCR, it does 
not incur extra cost and is considerably cheaper than 
the LiPA assay. Third, compared with conventional 
PCR, COLD-PCR does not increase the run time of 
experiment.
 Nevertheless, COLD-PCR has certain 
limitations. First, it may enrich minority species 
at other positions, thereby increasing the chance 
of obtaining high background sequencing noise. 
COLD-PCR may also induce a higher rate of 
PCR amplification error. This shortcoming can 
be overcome by using polymerases with proof-
reading activities. In addition, as numerous possible 
quasispecies can be found in HBV clinical isolates, 
a single empirically determined Tc may not be 
applicable to all possible viral variations within the 
quasispecies population. Nevertheless, it is expected 
that this experimentally determined Tc would at least 
enhance the detection of minor mutations, and this 
was proven in the present study with both cloned 
plasmids and clinical specimen.
 In a research setting, there are other more 
advanced methods to detect minor mutations, 
such as mass spectrometry, DNA microarray, next-
generation sequencing, or ultradeep pyrosequencing. 
These methods are generally more expensive than 
COLD-PCR, especially when the number of samples 
tested is small. COLD-PCR is an affordable choice 
in the sensitive detection of minor mutations, 
especially in under-developed areas. 
Conclusion
This study demonstrated that COLD-PCR could 
sensitively detect HBV drug resistance mutations 
at a level of 5-10% of the total viral population. It 
is simple and inexpensive and has the advantage of 
detecting novel mutations along the HBV reverse 
transcriptase gene.
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